Macron gains ground in latest Opinionway poll

Visteon CEO cashes $4.6M in options; sale pre-planned, ownership remains high.

STC drops 20% to $58.93. EPS fell 4.8% yearly, but BVPS grew 7.6%. Valuation is 1x P/B.

Meta's stock dips on AI spend, but trades at 20x forward earnings, a bargain for its $201B revenue.

Harbinger's flexible EV platform lands Frazer deal for ambulances, boosting its $300M+ funding.

Royalty Pharma's 31.5% gain is tempting, but tepid growth & lack of scale at 8.7x P/E raise risk.

Gold stocks NEM & B sink 20%+ on inflation/rate fears. Buy the dip? NEM EPS up 123%, B FCF up 194%.

CUBI's 1.5% return & 3.2% NIM signal weak loan book. Valuation's fair, but fundamentals show downside risk.